Importance: Acanthamoeba keratitis is a debilitating eye disease that requires effective topical drug therapy. Currently, there is no standard in vitro test to evaluate anti-Acanthamoeba drugs.
Objective: To develop a practical in vitro complete-kill assay to assess anti-Acanthamoeba drugs.
Purpose: To assess the long-term biocompatibility and photochromic stability of a new photochromic hydrophobic acrylic intraocular lens (IOL) under extended ultraviolet (UV) light exposure.
Setting: John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
Purpose: To test a visual model by looking at the differences in effect of Zymar((R)) (gatifloxacin plus benzalkonium chloride [BAK]) when compared to gatifloxacin and a normal saline (NS) control upon a methicillin and gatifloxacin-resistant Staphylococcus aureus (MRSA) species.
Methods: An ocular isolate of gatifloxacin-resistant (minimal inhibitory concentration >2 to 4 microg/mL) MRSA was grown to confluency. Chambered slides were prepared with bacterial culture smears, and then incubated with either gatifloxacin at the concentrations of 1 and 10 microg/mL, Zymar containing equivalent concentrations of gatifloxacin, or NS.
Background: The use of dispersive ophthalmic viscosurgical devices (OVDs) has been shown to provide significant protection against air bubble damage to the corneal endothelium when compared with cohesive OVDs. We compared the corneal endothelial protective effects of a new dispersive OVD, Healon-D, with Viscoat.
Methods: Healon-D and Viscoat were used in a randomized and masked fashion in the anterior chamber of 40 rabbit eyes during a procedure where ultrasound at 70% continuous energy was delivered for 2 min.
Purpose Of Review: To describe the condition known as intraoperative floppy iris syndrome in association with systemic alpha-1 blocker use in patients undergoing cataract surgery and techniques to prevent related complications.
Recent Findings: In recent years, an unexpected complication of progressive intraoperative miosis, iris billowing, and prolapse was noted during routine phacoemulsification in patients with current or previous use of alpha-1 adrenergic receptor antagonists. The syndrome is particularly prevalent among patients treated with tamsulosin, an alpha-1A blocker prescribed for the treatment of benign prostatic hyperplasia.